Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
Kemper M; Evers G; Schulze AB; Sperveslage J; Schülke C; Lenz G; Herold T; Hartmann W; Schildhaus HU; Bleckmann A
Research article (journal) | Peer reviewedDetails about the publication
Journal: Oncotarget
Volume: 13
Page range: 1216-1216
Status: Published
Release year: 2022 (02/11/2022)
Language in which the publication is written: English
Link to the full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448518/
Keywords: ALK; ALK inhibitors; KRAS; NSCLC; resistance mutations.
Authors from the University of Münster
| Bleckmann, Annalen | Westdeutsches Tumorzentrum (WTZ) Netzwerkpartner Münster |
| Evers, Georg | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Hartmann, Wolfgang | Gerhard Domagk Institute of Pathology |
| Kemper, Marcel | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Lenz, Georg | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Schülke, Christoph | Clinic of Radiology |
| Schulze, Arik Bernard | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Sperveslage, Jan | Gerhard Domagk Institute of Pathology |